On Wednesday, Shares of VIVUS, Inc. (NASDAQ:VVUS), gained 5.36% to $1.18.
VIVUS, offered a business update, stated its financial results for the second quarter ended June 30, 2015 and declared a restructuring plan.
Mr. Fischer continued, “We are working with leading cardiovascular outcome trial experts in planning substantial revisions to the original design and execution of the FDA-required Qsymia cardiovascular outcomes trial (CVOT) known as AQCLAIM, with the aim of reducing costs while also fulfilling the requirement of further demonstrating the long-term cardiovascular safety of Qsymia. We met recently with the FDA to provide a CVOT program update. This dialog is ongoing, and we are committed to involving the FDA in reviewing alternative proposals that will satisfy the existing requirements.”
VIVUS is actively pursuing a commercial partnership for avanafil in Latin America, and the Company plans to make declaration as soon as an alliance is secured. VIVUS is happy with the plans being executed presently by its STENDRA and SPEDRA commercialization partners to integrate the 15-minute onset of action data into their promotional campaigns.
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union.
Shares of Cameron International Corporation (NYSE:CAM), inclined 2.75% to $2.75, during its last trading session.
Cameron, planned to hold a conference call on Thursday, October 22, 2015 at 9:30 a.m. eastern time to talk about its financial results for the third quarter of 2015. The company anticipates to issue a press release on its quarterly financial results the same day, before the U.S. markets open.
Cameron International Corporation provides flow equipment products, systems, and services worldwide. The company’s Subsea segment offers integrated solutions, products, systems, and services to the subsea oil and gas market, counting integrated subsea production systems involving wellheads, subsea trees, manifolds and flowline connectors, and subsea processing systems.
At the end of Wednesday’s trade, Shares of Western Refining, Inc. (NYSE:WNR), gained 0.36% to $50.24.
Western Refining stated results for its second quarter ending June 30, 2015. Net income attributable to Western, not taking into account special items, was $138 million, or $1.44 per diluted share. This compares to second quarter 2014 net income, not taking into account special items, of $128.8 million, or $1.29 per diluted share. Counting special items, the Company recorded second quarter 2015 net income attributable to Western of $133.9 million, or $1.40 per diluted share, as contrast to net income attributable to Western of $156.7 million, or $1.56 per diluted share for the second quarter of 2014. A reconciliation of stated earnings and description of special items can be found in the accompanying financial tables.
Jeff Stevens, Western’s President and Chief Executive Officer, said, “This was another outstanding quarter for all of our business segments. Our refineries ran at historically high throughput rates in a strong margin environment and expenses were in line with expectations. In our Retail business, we saw an enhance in same store fuel volumes, fuel margins, and merchandise sales. NTI and WNRL also performed well in the quarter which contributed to our solid financial results.”
Western paid a dividend of $0.34 per share of common stock to shareholders in the second quarter. In July, Western’s Board of Directors approved a $0.34 per share dividend for the third quarter. Counting the third quarter dividend, Western will have returned about $118 million to shareholders through dividends and share repurchases to date in 2015.
Western Refining, Inc. operates as an independent crude oil refiner and marketer of refined products. The company operates in four segments: Refining, NTI, WNRL, and Retail. The Refining segment owns and operates two refineries that process crude oil and other feed stocks primarily into gasoline, diesel fuel, jet fuel, and asphalt; and markets refined products to various customers, counting wholesale distributors and retail chains
Finally, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ended its last trade with -0.80% loss, and closed at $244.03.
Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results.
2015 Second Quarter Results
- Total Revenue $2.7 billion; an enhance of 34% over the preceding year
- Not taking into account negative impact of foreign exchange ($173 million) and the contribution of Salix ($313 million), revenue raised 27% over the preceding year
- Same Store Sales Organic Growth was 19%, driven by:
- S. businesses, driven by the strength of dermatology, contact lenses, dental and Obagi
- Emerging markets counting China, the Middle East/North Africa, and Russia
- GAAP EPS Loss of $0.15; Cash EPS $2.56
- Not taking into account negative impact of foreign exchange ($0.13) and the negative contribution of Salix ($0.04) , Cash EPS would have been $2.73, a growth rate of 43%
- GAAP Operating Cash Flow $411 million; Adjusted Operating Cash Flow $773 million
- Not taking into account Salix, GAAP Operating Cash Flow $714 million
- Salix Revenue was $313 million
- Strong Xifaxan script uptake following IBS-D approval
- Salix wholesaler inventory levels reduced from 4-5 months to 3-3.5 months
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
